new glp 1 drugs in development Market Overview: GLP-1 Agonists and the Obesity Market | Blog What to know about the
Description
GLP-1 receptor agonists, which as the glucose-lowering therapeutic agents in the treatment of type 2 diabetes mellitus, have been shown to affect the incidence of cardiovascular outcomes in patients with type 2 diabetes mellitus, although the results regarding GLP-1 receptor agonists remain inconsistent [3, 4]
Patients should also report any side effects they experience , particularly severe, persistent abdominal pain (with or without vomiting) which could suggest pancreatitis or gallbladder disease and requires urgent medical review
L., Davies, M., et al
doi: 10.1016/j.nlm.2010.02.002 [DOI] [PMC free article] [PubMed] [Google Scholar] 56
